Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 3 of 3 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/15/17
End: 03/01/21
Due: 03/01/22
Phase: N/A
Priority: Normal
Start: 07/31/14
End: 04/01/25
Due: 04/01/26
Phase: N/A
Priority: Normal
Start: 04/24/18
End: 08/31/22
Due: 08/31/23
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Phase 1/2a Dose-Finding Study of PT-112 in Patients With Relapsed or Refractory Multiple Myeloma | NCT03288480 | Promontory Therapeutics Inc. | user2@example.com | None | 2017-12-15 | 2021-03-01 | 2022-03-01 | - | - | 2025-07-14 |
| A Study Evaluating the Safety, Pharmacokinetics, and Clinical Effects of Intravenously Administered PT-112 Injection in Subjects With Advanced Solid Tumors and Subsequent Dose Expansion Cohorts | NCT02266745 | Promontory Therapeutics Inc. | user2@example.com | None | 2014-07-31 | 2025-04-01 | 2026-04-01 | - | - | 2025-07-14 |
| A Dose Escalation and Confirmation Study of PT-112 in Advanced Solid Tumors in Combination With Avelumab | NCT03409458 | Promontory Therapeutics Inc. | user2@example.com | None | 2018-04-24 | 2022-08-31 | 2023-08-31 | - | - | 2025-07-14 |